AbCellera's investigational antibody medicine ABCL635 has set a new efficacy benchmark for treating menopausal hot flashes, with an 83% mean reduction in moderate-to-severe vasomotor symptoms (VMS) frequency after four weeks compared with 33% in placebo, achieving a placebo-adjusted treatment difference of 5.3 fewer hot flashes per day and statistically significant improvements in severity and sleep disruption; the Phase 2 results position ABCL635 as a potential best-in-class, non-hormonal, long-acting, subcutaneous treatment for menopause-related VMS, prompting strong investor interest and a sharp rise in AbCellera's stock (NASDAQ:
ABCL) following the announcement on August 10, 2026.
Sources:
AbCellera's menopause medicine 'sets new efficacy bar' for ...
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% ...
AbCellera stock soars on ‘off the chart' trial results from hot flash treatment for menopausal women
Now All Eyes Are On AbCellera's Menopause Drug Data
AbCellera's menopause drug reduces hot flashes in mid-stage trial
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam